Lincoln Pharmaceuticals: Profits Soar by 24.51% in Q1 2024-25

Lincoln Pharmaceuticals reported a 24.51% increase in net profit for Q1 2024-25, reaching Rs 23.67 crore. The company's total income rose to Rs 157.69 crore, led by growth in both domestic and export markets. Operating profit increased by 16.65%, and the company has ambitious revenue targets for FY26.

Lincoln Pharmaceuticals has announced a substantial 24.51% increase in its consolidated net profit, amounting to Rs 23.67 crore for the first quarter of 2024-25. This marks a significant rise from Rs 19.01 crore in the same period a year ago.

The Ahmedabad-based company's total income surged by 10% to Rs 157.69 crore for the quarter, up from Rs 143.31 crore in the first quarter of the previous fiscal year. Operating profits, represented by EBITDA, also saw a robust growth of 16.65%, reaching Rs 33.14 crore.

Driven by strong performance in both domestic and international markets, Lincoln Pharmaceuticals remains optimistic about its profitability and margins. The company has set a revenue target of Rs 750 crore for FY26, focusing on value-added products and market expansion. Shares of the company closed at Rs 652.75 on BSE, down by 0.95%.

(With inputs from agencies.)